Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $9.00 price target ...

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.67 per share a year ago. These figures are ...

Reports FY24 revenue $25.3M, consensus $25.15M. “We are pleased with the significant PEMGARDA revenue growth of 48% in the fourth quarter, ...

Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 ...

2; affirms structural biology within Invivyd's unique technology and reflects consistently stable epitope for pemivibart VYD2311 also demonstrates stable epitope and clinically meaningful in vitro ...

March 05, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA™ (pemivibart) against the currently ...

2; affirms structural biology within Invivyd’s unique technology and reflects consistently stable epitope for pemivibart VYD2311 also demonstrates stable epitope and clinically meaningful in ...

Invivyd has seen its share price surge by an impressive 163% over the past month, driven primarily by the positive data released from its Phase 1/2 clinical trial of VYD2311, a novel monoclonal ...

Feb. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced preliminary ...